Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 222

Sort by

Sort Order Select

Journal Articles

A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort

Blood (2024) 144 (22): 2360–2363.

https://doi.org/10.1182/blood.2024025834

Published: 2024

Includes: Supplemental data

Journal Articles

BCMA CART Therapy Failure in Myeloma Is Associated with Immunosuppressive S100A8/9 Overexpression and Can be Ameliorated with Novel Monoclonal Antibodies

Adolfo Aleman, Rongbao Zhao, Leah Grossman, Rahul Sanawar, Srinivas Aluri, Mani Mohindru, Rudra Prasad Dutta, Sidorela Reci, Junia Vieira, David Melnekoff, Alessandro Lagana, Shriya Desai, Sundar Jagannath, Amit Verma, Samir Parekh

Blood (2024) 144 (Supplement 1): 589.

https://doi.org/10.1182/blood-2024-201194

Published: 2024

Journal Articles

Decitabine Activity Against TP53 -Mutated Myeloid Neoplasms Is Enhanced By Combination with a Non-Cytotoxic p53/BAX-Independent Inhibitor of Pyrimidine Synthesis

Sudipta Biswas, Zeinab Albadry M. Zahran, Xiaorong Gu, Lisa Cardone, Akriti G. Jain, Kateryna Fedorov, Ben K. Tomlinson, Mendel Goldfinger, Amit Verma, Yogenthiran Saunthararajah

Blood (2024) 144 (Supplement 1): 1382.

https://doi.org/10.1182/blood-2024-210609

Published: 2024

Journal Articles

North American Adult T-Cell Leukemia Lymphoma Has Frequent Mutations in CCR4 and Responds in Vitro to a Small Molecule CCR4 Antagonist

Eric Liu, Amit Verma, Kith Pradhan, Urvi A. Shah, Aditi Shastri, Erik Guillen, Alejandro Sica, Gregoire Lauvau, Murali Janakiram, Paul D. Kassner

Blood (2024) 144 (Supplement 1): 1591.

https://doi.org/10.1182/blood-2024-210385

Published: 2024

Journal Articles

Venetoclax Combined with “7+3” Induction Chemotherapy Induces High MRD-Negative Response Rates in Newly Diagnosed AML Patients Fit for Intensive Chemotherapy across Ages

Blood (2024) 144 (Supplement 1): 57.

https://doi.org/10.1182/blood-2024-211685

Published: 2024

Journal Articles

Selective SMARCA2 Degradation Promotes Leukemic Differentiation and Synergizes with CDK9 Inhibition to Potently Induce Death in Pre-Clinical Models of Acute Myeloid Leukemia

Norman Fultang, Ashley M Schwab, Ian Johnson, Alexander Grego, Emma Filler, Carly Bachner, Jake Karwoski, Andrew Moore, Ashley Bartilomo, Anjana Agarwal, Olusola Peace Osinubi, Koichi Ito, Sarah Aminov, Srabani Sahu, Amit Verma, Peggy A Scherle, Neha Bhagwat, Diane Heiser

Blood (2024) 144 (Supplement 1): 2774.

https://doi.org/10.1182/blood-2024-208196

Published: 2024

Journal Articles

Venetoclax Alone or in Combination Shows Promising Activity in Preclinical Models and Clinical Cases of Relapsed/Refractory North American Adult T-Cell Leukemia Lymphoma

Blood (2024) 144 (Supplement 1): 2791.

https://doi.org/10.1182/blood-2024-206160

Published: 2024

Journal Articles

Assessing the Performance of the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Model in a Multicultural Bronx Cohort: Implications for Monoclonal Gammopathy of Undetermined Significance (MGUS) Risk Stratification

Blood (2024) 144 (Supplement 1): 3307.

https://doi.org/10.1182/blood-2024-201590

Published: 2024

Journal Articles

Phase Ib Study of PRT543, an Oral Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Patients with Relapsed or Refractory, Splicing Factor-Mutant Myeloid Malignancies

Jan Philipp Bewersdorf, Xiaoli Mi, Bin Lu, Andrew T. Kuykendall, David Sallman, Manish Patel, Don A. Stevens, Alexander Philipovskiy, Grerk Sutamtewagul, Lucia Masarova, Gina Keiffer, Amit Verma, Neha Bhagwat, Diane Heiser, Sunhee Ro, Wan-Jen Hong, Omar Abdel-Wahab, Eytan M. Stein

Blood (2024) 144 (Supplement 1): 3215.

https://doi.org/10.1182/blood-2024-198495

Published: 2024

Journal Articles

Degrading SMARCA2/4 Relieves the Differentiation Block in AML Via Chromatin Alterations Affecting S100A8/9

Blood (2024) 144 (Supplement 1): 2909.

https://doi.org/10.1182/blood-2024-198479

Published: 2024

Journal Articles

Developments in Therapeutics and Impact on AML Survival in Older Patients: A Populational Analysis

John X Wei, Mendel Goldfinger, Marina Konopleva, Ioannis Mantzaris, Amit Verma, Eric J. Feldman

Blood (2024) 144 (Supplement 1): 3802.

https://doi.org/10.1182/blood-2024-206488

Published: 2024

Journal Articles

Preliminary Safety, Efficacy and Molecular Characterization in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Single Agent Emavusertib (CA-4948)

Guillermo Garcia-Manero, David Sallman, Stefano R Tarantolo, Amit Verma, Stefanie Groepper, Alice Mims, Yasmin Abaza, James P. Dugan, Valle Gomez G De Soria, Gaurav S Choudhary, Maureen Lane, Wanying Zhao, Ashish Jain, Cole Gallagher, Uwe Platzbecker

Blood (2024) 144 (Supplement 1): 3225.

https://doi.org/10.1182/blood-2024-208292

Published: 2024

Journal Articles

Promising Safety and Efficacy Data for Peginterferon Alfa-2a (PEG-IFN) and Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy) in a North American Adult T-Cell Leukemia Lymphoma (NA-ATLL) Cohort of Patients

Blood (2024) 144 (Supplement 1): 3067.

https://doi.org/10.1182/blood-2024-208199

Published: 2024

Journal Articles

Assessing the Utility of Interim Bone Marrow Results in Acute Myeloid Leukemia Induction

Blood (2024) 144 (Supplement 1): 6175.

https://doi.org/10.1182/blood-2024-208911

Published: 2024

Journal Articles

A Phase 1 Study Investigating the Safety and Efficacy of Danvatirsen As Monotherapy Followed By Combination with Venetoclax in Patients with Relapsed/Refractory MDS and AML

Blood (2024) 144 (Supplement 1): 4265.5.

https://doi.org/10.1182/blood-2024-208998

Published: 2024

Journal Articles

Impact of Patient and Donor Factors on Successful Hematopoietic Stem Cell Transplantation for Acute T-Cell Leukemia/Lymphoma Patients in an Underserved Minority Population

Blood (2024) 144 (Supplement 1): 4443.

https://doi.org/10.1182/blood-2024-211956

Published: 2024

Journal Articles

Elevated Clonal Hematopoiesis in Environmentally Exposed Responders Has Distinct Age-Related Patterns and Relies on IL1RAP for Clonal Expansion

Blood (2024) 144 (Supplement 1): 943.

https://doi.org/10.1182/blood-2024-194127

Published: 2024

Journal Articles

KRAS G12D Specific Inhibitors Relieve Erythroid Differentiation Block and Modulate Inflammatory Pathways at the Single Cell Level in Myeloid Malignancies

Leah Kravets, Mirca S. Saurty-Seerunghen, Divij Verma, Ariel Fromowitz, Srabani Sahu, Bradley Rockwell, Olivia Sakaguchi, Swathi Narayanagari, Shanisha Gordon Mitchell, Milagros Carbajal, Srinivas Aluri, Jingli Wang, Lindsay Lafave, Marina Konopleva, Anna S. Nam, Amit Verma

Blood (2024) 144 (Supplement 1): 326.

https://doi.org/10.1182/blood-2024-208924

Published: 2024

Journal Articles

TGF-β1-SMAD2 Axis Regulates Hematopoiesis and β-Globin Gene Expression Via Super-Enhancer Associated Chromatin Reorganization

Blood (2024) 144 (Supplement 1): 878.

https://doi.org/10.1182/blood-2024-201101

Published: 2024

Journal Articles

Efficacy of Cladribine, Low-Dose Cytarabine, and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia in a High-Risk Ethnically Diverse Cohort

John Yan, Josette Kamel, Amit Verma, Eric J. Feldman, Dennis L Cooper, Lauren Shapiro, Ridhi Gupta, Nishi Shah, Noah Kornblum, David Levitz, R. Alejandro Sica, Kira Gritsman, Aditi Shastri, Ioannis Mantzaris, Mendel Goldfinger, Marina Konopleva

Blood (2024) 144 (Supplement 1): 5966.

https://doi.org/10.1182/blood-2024-212222

Published: 2024

NARROW

A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort

BCMA CART Therapy Failure in Myeloma Is Associated with Immunosuppressive S100A8/9 Overexpression and Can be Ameliorated with Novel Monoclonal Antibodies

Decitabine Activity Against TP53 -Mutated Myeloid Neoplasms Is Enhanced By Combination with a Non-Cytotoxic p53/BAX-Independent Inhibitor of Pyrimidine Synthesis

North American Adult T-Cell Leukemia Lymphoma Has Frequent Mutations in CCR4 and Responds in Vitro to a Small Molecule CCR4 Antagonist

Venetoclax Combined with “7+3” Induction Chemotherapy Induces High MRD-Negative Response Rates in Newly Diagnosed AML Patients Fit for Intensive Chemotherapy across Ages

Selective SMARCA2 Degradation Promotes Leukemic Differentiation and Synergizes with CDK9 Inhibition to Potently Induce Death in Pre-Clinical Models of Acute Myeloid Leukemia

Venetoclax Alone or in Combination Shows Promising Activity in Preclinical Models and Clinical Cases of Relapsed/Refractory North American Adult T-Cell Leukemia Lymphoma

Assessing the Performance of the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Model in a Multicultural Bronx Cohort: Implications for Monoclonal Gammopathy of Undetermined Significance (MGUS) Risk Stratification

Phase Ib Study of PRT543, an Oral Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Patients with Relapsed or Refractory, Splicing Factor-Mutant Myeloid Malignancies

Degrading SMARCA2/4 Relieves the Differentiation Block in AML Via Chromatin Alterations Affecting S100A8/9

Developments in Therapeutics and Impact on AML Survival in Older Patients: A Populational Analysis

Preliminary Safety, Efficacy and Molecular Characterization in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Single Agent Emavusertib (CA-4948)

Promising Safety and Efficacy Data for Peginterferon Alfa-2a (PEG-IFN) and Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy) in a North American Adult T-Cell Leukemia Lymphoma (NA-ATLL) Cohort of Patients

Assessing the Utility of Interim Bone Marrow Results in Acute Myeloid Leukemia Induction

A Phase 1 Study Investigating the Safety and Efficacy of Danvatirsen As Monotherapy Followed By Combination with Venetoclax in Patients with Relapsed/Refractory MDS and AML

Impact of Patient and Donor Factors on Successful Hematopoietic Stem Cell Transplantation for Acute T-Cell Leukemia/Lymphoma Patients in an Underserved Minority Population

Elevated Clonal Hematopoiesis in Environmentally Exposed Responders Has Distinct Age-Related Patterns and Relies on IL1RAP for Clonal Expansion

KRAS G12D Specific Inhibitors Relieve Erythroid Differentiation Block and Modulate Inflammatory Pathways at the Single Cell Level in Myeloid Malignancies

TGF-β1-SMAD2 Axis Regulates Hematopoiesis and β-Globin Gene Expression Via Super-Enhancer Associated Chromatin Reorganization

Efficacy of Cladribine, Low-Dose Cytarabine, and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia in a High-Risk Ethnically Diverse Cohort

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only